UNSPSC 51161727: Doxapram hydrochloride

This classification denotes a cns stimulant with the molecular formula C24H30N2O2.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P5RU6UOQ5Y, chemically known as 2-pyrrolidinone, 1-ethyl-4- (2-morpholinoethyl)-3,3-diphenyl-, monohydrochloride but more generally known as doxapram hydrochloride, which bears US NIH Compound Identifier 3156. European Medicines Agency schedules Doxapram hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01823MIG.

UNSPSC 51161727 Doxapram hydrochloride, a Commodity code, shows limited recent activity directly targeting this specific pharmaceutical product, though the posting record captures tangential pharmacy and pharmaceutical procurement across state and local jurisdictions. The recent opportunities reveal that state and local governments are buying naloxone and drug-deactivation systems, on-site pharmacy services for employee health plans, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploring direct-to-manufacturer prescription programs—none of which center on doxapram itself. The code appears to reflect a narrow specialty pharmaceutical niche that does not align with the current procurement focus visible in the recent solicitations, which concentrate on broader pharmacy benefit management, emergency naloxone stockpiling, and generic medication supply chains rather than specific respiratory-stimulant or analeptic agents.

Issuing bodies in the recent record span county health departments (Seminole County, Florida for naloxone procurement), county government health centers (Hall County, Georgia for on-site pharmacy services), state-level health agencies (Texas Health and Human Services Commission for direct-to-manufacturer pharmacy initiatives), and regional multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance for generic pharmaceuticals serving state and local facilities across multiple states including Oregon). Geographic activity clusters in Florida, Georgia, Texas, and the upper Midwest, with the MMCAP cooperative extending reach across multiple participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 drug-deactivation systems annually; Hall County's RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at the Family Health Center Clinic; and the Texas HHS RFI HHS0017013 (April 3, 2026) exploring direct-to-manufacturer prescription capabilities. The Minnesota MMCAP RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals represents the largest-scope cooperative procurement, though it does not specifically target doxapram.